Bone Health in Adolescents and Young Adults With Oral Macro-progestin Treatment (MACROS)
|The safety and scientific validity of this study is the responsibility of the study sponsor and investigators. Listing a study does not mean it has been evaluated by the U.S. Federal Government. Know the risks and potential benefits of clinical studies and talk to your health care provider before participating. Read our disclaimer for details.|
|ClinicalTrials.gov Identifier: NCT04007614|
Recruitment Status : Not yet recruiting
First Posted : July 3, 2019
Last Update Posted : July 3, 2019
Many factors are known to influence the acquisition of bone capital, especially estrogens in women. Estrogens have a major role in bone growth and the acquisition of bone mass peaks during puberty. This peak of bone mass is an important determinant of the risk of osteoporotic fracture in adulthood.
It is known that estrogen deficiency increases the rate of bone remodeling and engenders an imbalance between resorption and bone formation, which can lead to osteoporosis.
Oral estroprogestin contraceptives have an anti-gonadotropic effect and suppress estrogen secretion by the ovaries.
However, studies in adolescents and young adults are rare and evidence of an effect on bone is still inconclusive, although there is increasing evidence that oral estroprogestin contraceptives in teenage girls may compromise the performance of the bone mass.
Macro progestins treatments are prescribed in France to patients with contraindications to estroprogestin treatments. This practice is french and few recommendations exist on the use of these molecules by the oral route. There are no studies that describe the impact of these oral treatments on the bone health of young women treated.
The Department of endocrinology, gynecology and pediatric diabetes of Necker-Enfants Malades hospital, follows many young girls taking a macro progestin treatment. This study is exclusively descriptive and will focus on the clinical and medical datas available on the bone health of these patients.
|Condition or disease||Intervention/treatment|
|Contraception Macro-progestins||Other: Questionnaire|
|Study Type :||Observational|
|Estimated Enrollment :||50 participants|
|Official Title:||Bone Health in Adolescents and Young Adults With Oral Macro-progestin Treatment : Observational Study|
|Estimated Study Start Date :||September 2019|
|Estimated Primary Completion Date :||July 2020|
|Estimated Study Completion Date :||July 2020|
Patients who have taken a macro progestin treatment for more than 6 months between 16 and 25 years of age.
Fardellone questionnaire (evaluation of calcium intake) Tolerance of treatment
- Bone densitometry [ Time Frame: Day 0 ]Z score values compared to the reference values
- Calcemia [ Time Frame: Day 0 ]Blood test
- Ionized calcium [ Time Frame: Day 0 ]Blood test
- Phosphor [ Time Frame: Day 0 ]Blood test
- Magnesium [ Time Frame: Day 0 ]Blood test
- Albumin [ Time Frame: Day 0 ]Blood test
- Parathormone [ Time Frame: Day 0 ]Blood test
- 25 OH vitamin D3 [ Time Frame: Day 0 ]Blood test
- Creatinine [ Time Frame: Day 0 ]Blood test
- Osteocalcin [ Time Frame: Day 0 ]Blood test
- Bone alkaline phosphatase isoenzymes [ Time Frame: Day 0 ]Blood test
- C-terminal telopeptide of type I collagen [ Time Frame: Day 0 ]Blood test
- Calciuria [ Time Frame: Day 0 ]Urine test
- Natriuresis [ Time Frame: Day 0 ]Urine test
- Creatinuria [ Time Frame: Day 0 ]Urine test
- Clinical tolerance of treatment [ Time Frame: Day 0 ]6 questions asked to the patient under treatment, a yes or no answer is expected : presence of menstruating, regularity of cycles, out-of-periods bleeding, weight gain, acne, satisfaction in relation to treatment.
- Follicle stimulating hormone [ Time Frame: Day 0 ]Blood test, patients under macro progestin treatment at day 0
- Gonadotrophin b LH [ Time Frame: Day 0 ]Blood test, patients under macro progestin treatment at day 0
- Estradiol [ Time Frame: Day 0 ]Blood test, patients under macro progestin treatment at day 0
To learn more about this study, you or your doctor may contact the study research staff using the contact information provided by the sponsor.
Please refer to this study by its ClinicalTrials.gov identifier (NCT number): NCT04007614
|Contact: Maud Bidet, MD||1 71 19 64 firstname.lastname@example.org|
|Contact: Hélène Morel||1 71 19 63 46 ext +email@example.com|
|Hôpital Necker-Enfants Malades||Not yet recruiting|
|Paris, France, 75015|
|Contact: Maud Bidet, MD 1 71 19 64 38 ext +33 firstname.lastname@example.org|
|Contact: Hélène Morel 1 71 19 63 46 ext +33 email@example.com|
|Study Director:||Sabrina Da Costa, MD||Hôpital Necker-Enfants Malades|